Europese Unie - Nederlands - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (als fosfaat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastische middelen - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi is geïndiceerd voor de behandeling van volwassen patiënten met polycythaemia vera die resistent of intolerant is voor hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.